Abstract:2616 Background: Metronomic chemotherapy which can modulate tumor microenvironment is a potential partner of PD-1 antibodies. The association between lipid metabolism and efficacy of immunotherapy is recognized but has not been reported in metronomic chemotherapy. We aimed to evaluate the feasibility of metronomic capecitabine plus camrelizumab as a salvage treatment for refractory gastrointestinal cancer patients and to explore the involvement of lipid metabolism in response to this combination therapy. Methods: In this single-center, exploratory trial, advanced GI cancer patients who had disease progression after standard chemotherapy were treated with metronomic capecitabine (500mg twice daily) plus camrelizumab (200mg on day 1 intravenously every 2 weeks). The primary endpoint was safety. For lipid metabolism, body composition analysis based on CT scans at L3 level and peripheral blood lipidomic analysis were performed. Associations between treatment efficacy and body composition parameters as well as differential plasma lipids were assessed. Plasma samples of GI cancer patients treated with PD-1 antibody-based therapy were detected by lipidomic analysis as a test cohort. Differential expressed genes of C2C12 cells treated with metronomic dose 5-fluorouracil in vitro were detected and pathway enrichment analysis was performed. Results: Twenty-six patients with esophageal (9), gastric (8), bile duct (5), or pancreatic cancer (3) were enrolled. Sixteen patients (61.5%) had ≥2 previous lines of chemotherapy and 11 patients were ECOG 2. Treatment emergent adverse events (TEAEs) grade ≥3 occurred in five patients (19.2%), including biliary tract infection (11.5%), fatigue (7.7%), and increased AST/ALT (3.8%). Three patients suffered severe AEs that were not related to treatment. Objective response rate was 19.2% (5/26) including two patients with complete response. High skeletal muscle radiation attenuation (SMRA) was associated with disease control and better survival of patients. Differential plasma lipids were identified in disease-controlled patients compared with those achieved disease progression. High level of a plasma 6-lipid signature composed of SM40:1;3, TG54:4-FA20:2, LPC (16:0), TG52:0-FA20:0, TG56:3-FA20:2, and PE(P-18:1/18:2) indicated better survival of patients and was confirmed in the test cohort. Differential plasma lipids were increased after treatment. Differential expressed genes in C2C12 cells after treatment were involved in lipid metabolism pathways. Conclusions: Metronomic capecitabine plus camrelizumab showed low rate of grade ≥3 AEs and promising efficacy in refractory GI cancer patients. Lipid metabolism modulation was associated with treatment response to this combination therapy. Clinical trial information: NCT04508686 , NCT04510818 , NCT04932187 .

Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration

Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells

Tumor-Targeted Inhibition of Monocarboxylate Transporter 1 Improves T-Cell Immunotherapy of Solid Tumors

Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies

Monocarboxylate Transporter-2 Expression Restricts Tumor Growth in a Murine Model of Lung Cancer: A Multi-Omic Analysis

Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma

MCT4 blockade increases the efficacy of immune checkpoint blockade

Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology

Abstract 2652: Efficacy of a small molecule MCT1 and MCT4 transporter inhibitor in cancer

Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer

Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: A review with structure-activity relationship insights

Immu-58. Bcat1 Targeted Metabolic Reprogramming Plays Critical Roles In Modulating Myeloid Derived Suppressor Cell Function In Glioblastoma

Targeting Lactate Metabolism by Inhibiting MCT1 or MCT4 Impairs Leukemic Cell Proliferation, Induces Two Different Related Death-Pathways and Increases Chemotherapeutic Sensitivity of Acute Myeloid Leukemia Cells

Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack

Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells

Antitumor effects of lactate transport inhibition on esophageal adenocarcinoma cells

Lactate/pyruvate transporter MCT-1 is a direct Wnt target that confers sensitivity to 3-bromopyruvate in colon cancer

Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects

The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models

Modulation of lipid metabolism associated with response to metronomic capecitabine plus camrelizumab in patients with refractory gastrointestinal cancer: A prospective, single-center, exploratory trial.

3-Bromopyruvate-mediated MCT1-dependent metabolic perturbation sensitizes triple negative breast cancer cells to ionizing radiation